AtriCure beats Q4 profit estimates

Reuters02-18

AtriCure beats Q4 profit estimates

Overview

Surgical treatment innovator's Q4 revenue rose 13.1% yr/yr
Adjusted EPS for Q4 beat analyst expectations
Adjusted EBITDA for Q4 beat analyst expectations

Outlook

AtriCure projects 2026 revenue of $600 mln to $610 mln, up 12% to 14% from 2025
Company expects 2026 adjusted EBITDA of $80 mln to $82 mln
AtriCure anticipates 2026 adjusted EPS of $0.09 to $0.15

Result Drivers

PRODUCT PERFORMANCE - Growth in Q4 revenue driven by cryoSPHERE MAX probe, AtriClip FLEX-Mini device, and EnCompass clamp
INTERNATIONAL GROWTH - International revenue increased by 15.3%, with growth in most key markets
FAVORABLE PRODUCT MIX - Gross margin increased due to a more favorable product mix

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Adjusted EPS	Beat	$0.06	-$0.10 (8 Analysts)
Q4 Adjusted EBITDA	Beat	$19.90 mln	$13.02 mln (8 Analysts)
Q4 Gross Margin		75.00%
Q4 Gross Profit		$105.30 mln
Q4 Operating Income		$2.50 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AtriCure Inc is $54.00, about 65.4% above its February 13 closing price of $32.65

Press Release: ID:nBw1446yva

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612601604?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612601604","market":"us","top_or_hot":-1,"title":"AtriCure beats Q4 profit estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>AtriCure beats Q4 profit estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Surgical treatment innovator's Q4 revenue rose 13.1% yr/yr</p></li><li><p>Adjusted EPS for Q4 beat analyst expectations</p></li><li><p>Adjusted EBITDA for Q4 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>AtriCure projects 2026 revenue of $600 mln to $610 mln, up 12% to 14% from 2025</p></li><li><p>Company expects 2026 adjusted EBITDA of $80 mln to $82 mln</p></li><li><p>AtriCure anticipates 2026 adjusted EPS of $0.09 to $0.15</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRODUCT PERFORMANCE - Growth in Q4 revenue driven by cryoSPHERE MAX probe, AtriClip FLEX-Mini device, and EnCompass clamp</p></li><li><p>INTERNATIONAL GROWTH - International revenue increased by 15.3%, with growth in most key markets</p></li><li><p>FAVORABLE PRODUCT MIX - Gross margin increased due to a more favorable product mix</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>$0.06</p></td><td><p>-$0.10 (8 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>$19.90 mln</p></td><td><p>$13.02 mln (8 Analysts)</p></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>75.00%</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$105.30 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>$2.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for AtriCure Inc is $54.00, about 65.4% above its February 13 closing price of $32.65</p></li></ul><p>Press Release: <span>ID:nBw1446yva</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AtriCure beats Q4 profit estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtriCure beats Q4 profit estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 05:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>AtriCure beats Q4 profit estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Surgical treatment innovator's Q4 revenue rose 13.1% yr/yr</p></li><li><p>Adjusted EPS for Q4 beat analyst expectations</p></li><li><p>Adjusted EBITDA for Q4 beat analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>AtriCure projects 2026 revenue of $600 mln to $610 mln, up 12% to 14% from 2025</p></li><li><p>Company expects 2026 adjusted EBITDA of $80 mln to $82 mln</p></li><li><p>AtriCure anticipates 2026 adjusted EPS of $0.09 to $0.15</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRODUCT PERFORMANCE - Growth in Q4 revenue driven by cryoSPHERE MAX probe, AtriClip FLEX-Mini device, and EnCompass clamp</p></li><li><p>INTERNATIONAL GROWTH - International revenue increased by 15.3%, with growth in most key markets</p></li><li><p>FAVORABLE PRODUCT MIX - Gross margin increased due to a more favorable product mix</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>$0.06</p></td><td><p>-$0.10 (8 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>$19.90 mln</p></td><td><p>$13.02 mln (8 Analysts)</p></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>75.00%</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$105.30 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>$2.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for AtriCure Inc is $54.00, about 65.4% above its February 13 closing price of $32.65</p></li></ul><p>Press Release: <span>ID:nBw1446yva</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1366192091.USD","symbol_name":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nL1N3ZD0XU:1","article_id":"2612601604","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612601604","pubTimestamp":1771362572,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AtriCure beats Q4 profit estimatesOverviewSurgical treatment innovator's Q4 revenue rose 13.1% yr/yrAdjusted EPS for Q4 beat analyst expectationsAdjusted EBITDA for Q4 beat analyst expectationsOutlook","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","BK4585":"ETF&股票定投概念","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0472753341.HKD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","BK4082":"医疗保健设备","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","ATRC":"AtriCure公司","BK4588":"碎股","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","BK4145":"电子制造服务","FLEX":"伟创力国际","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","BK4512":"苹果概念","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0054578231.USD":"BGF SYSTEMATIC SUSTAINABLE GLOBAL SMALLCAP \"A2\" (USD) ACC"},"translate_title":"AtriCure第四季度利润超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATRC":0.9,"FLEX":0.9},"content_text":"AtriCure beats Q4 profit estimatesOverviewSurgical treatment innovator's Q4 revenue rose 13.1% yr/yrAdjusted EPS for Q4 beat analyst expectationsAdjusted EBITDA for Q4 beat analyst expectationsOutlookAtriCure projects 2026 revenue of $600 mln to $610 mln, up 12% to 14% from 2025Company expects 2026 adjusted EBITDA of $80 mln to $82 mlnAtriCure anticipates 2026 adjusted EPS of $0.09 to $0.15Result DriversPRODUCT PERFORMANCE - Growth in Q4 revenue driven by cryoSPHERE MAX probe, AtriClip FLEX-Mini device, and EnCompass clampINTERNATIONAL GROWTH - International revenue increased by 15.3%, with growth in most key marketsFAVORABLE PRODUCT MIX - Gross margin increased due to a more favorable product mixKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Adjusted EPSBeat$0.06-$0.10 (8 Analysts)Q4 Adjusted EBITDABeat$19.90 mln$13.02 mln (8 Analysts)Q4 Gross Margin75.00%Q4 Gross Profit$105.30 mlnQ4 Operating Income$2.50 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy\"Wall Street's median 12-month price target for AtriCure Inc is $54.00, about 65.4% above its February 13 closing price of $32.65Press Release: ID:nBw1446yvaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612601604","isCrawlerRequest":true}